patritumab,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['patritumab', 'mbc', 'tnbc']
#asco2022 krop phase 1/2 study of patritumab deruxtecan, a her3-directed adc in her3-expressing mbc. same tox as t-dxd. ongoing study. 2-6 prior lines of ct, 1-2 in tnbc.
Professor of Medicine, Stanford University; breast cancer doc